Ketek Risk Cannot Be Distinguished From Class, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Labeling for Sanofi-Aventis’ macrolide antibiotic telithromycin increases warnings about liver toxicity and myasthenia gravis.
You may also be interested in...
Ketek Act I: FDA Updates Label, Touts Process On Eve Of Hearing
Agency says it has “learned” from controversy surrounding the antibiotic, but FDA will likely still face congressional grilling about its actions.
Ketek Act I: FDA Updates Label, Touts Process On Eve Of Hearing
Agency says it has “learned” from controversy surrounding the antibiotic, but FDA will likely still face congressional grilling about its actions.
Ketek Medication Guide Suggested By FDA Staff
Two-day, two-panel advisory committee meeting will consider the risks and benefits of the antibiotic, which Sanofi-Aventis says addresses an unmet medical need.